Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domatinostat plus avelumab in previously treated mismatch repair proficient oesophagogastric and colorectal cancers
2017-001770-42Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Domatinostat and avelumab in gastroesophageal junction adenocarcinoma and colorectal cancer (CRC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Efficacy of domatinostat added to avelumab and Radiological response. Status: unknown.
02
Drugs
Domatinostatavelumab
03
Conditions
gastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2017-001770-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001770-42.